SK pharmteco’s Post

Explore Veradigm’s groundbreaking approach to healthcare and life sciences. Learn from Veradigm's President & CCO, Tom Langan, about our unique network and innovative strategies in Newsweek’s New Era of Life Sciences 2024 Report.

𝐔𝐍𝐕𝐄𝐈𝐋𝐈𝐍𝐆 𝐅𝐔𝐓𝐔𝐑𝐄 𝐇𝐄𝐀𝐋𝐓𝐇 𝐂𝐎𝐌𝐏𝐀𝐍𝐈𝐄𝐒 𝐎𝐍 𝐀 𝐆𝐋𝐎𝐁𝐀𝐋 𝐒𝐂𝐀𝐋𝐄 It's thrilling to reflect on the incredible journey our team has embarked on, contributing to the advancement of key players in #lifesciences and establishing promising, scalable partnerships with emerging companies to address critical #globalhealth challenges. In this article, I'll recap the numerous initiatives hosted, co-designed, and promoted by Frontiers Health across eight global editions, demonstrating our unwavering commitment to enhancing and serving the global #healthinnovation ecosystem. From Start-up Discoveries and pitch competitions to awards ceremonies, closed-door meetings, and accelerators cohorts'presentations, we've employed various formats to empower those shaping our ever-evolving space. 👉 https://lnkd.in/dd9uuwBN As we look ahead to 2024, we're eager to hear from industry leaders about how we can support your plans, projects, and initiatives to drive the #futureofhealth. Reach out to us, and let's make magic happen! https://lnkd.in/dKfAxvWU #FH24 #digitalhealth #lifesciences #pharma #biopharma #telehealth #artificialintelligence #virtualcare #digitalmedicine

Refreshing keynote by Veronika von Messling from Bundesministerium für Bildung und Forschung at #JTHOP – what do we expect from future #healthcare? How can we address challenges along the value chain? How can basic research deliver to power future healthcare? Part of our #Cluster4Future mission is to develop strategies that address these questions – and we echo many of the aspects presented! We need to 👉 minimize losses along the (usually lengthy) #drugdisovery journey 🖥 embrace changes associated with e.g. in silico research 👥 build partnerships, get out of our comfort zone & seize chances Let’s do it! 🚀

This week, our COO, Kate Woolland, joined IQVIA UK and Ireland , together with a panel of experts, to discuss how to overcome the challenges hindering the adoption of accelerated innovation in the healthcare and life science industry, for the latest installment of "Making Market Access Real".   The main topic of discussion revolved around the unsustainability of healthcare in its current form. Challenges in funding, productivity, workforce shortages, and the backlog in the post-pandemic era, along with health equity and access issues, create significant obstacles. Innovation plays a fundamental part in tackling these challenges. However, it is not the innovation itself but the adoption of innovation that presents the biggest challenge for the industry.   💡 At Closed Loop Medicine, our aim is to provide a pathway for all individuals to access high-quality personalized treatment, addressing the current shortfall in scalable personalized healthcare solutions, by enabling real-time, real-world drug dose optimization of both new and established medicines – offering precision care for all while supporting healthcare providers.   If you haven’t already, watch the video to join the conversation on what’s happening to drive innovation forward. 👇   #Healthcare #Innovation #NHS #PrecisionCare 

Research estimates that 𝟒𝟒% of Digital Health startups reach the market with 𝐥𝐨𝐰 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐫𝐨𝐛𝐮𝐬𝐭𝐧𝐞𝐬𝐬. [https://lnkd.in/gn4jTHPK] That’s why we've built 𝐖𝐨𝐫𝐭𝐡𝐦𝐞𝐝, a platform designed to revolutionize the landscape of digital health by connecting innovators and researchers together. Worthmed 𝐬𝐮𝐩𝐩𝐨𝐫𝐭𝐬 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐨𝐫𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐜𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐯𝐞 𝐝𝐞𝐬𝐢𝐠𝐧, 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭, 𝐚𝐧𝐝 𝐯𝐚𝐥𝐢𝐝𝐚𝐭𝐢𝐨𝐧 of digital health solutions, using innovative participatory methods based on real-world evidence. Discover how 𝐖𝐨𝐫𝐭𝐡𝐦𝐞𝐝 can empower your solution on the leaflet below and at worthmed.com 𝗕𝗿𝗶𝗻𝗴𝗶𝗻𝗴 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗮𝗻𝗱 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝘁𝗼𝗴𝗲𝘁𝗵𝗲𝗿!

🧬 This week's Austin Bio + Health Roundup highlights significant data trends, my stance on covering funding announcements, new partnerships, and action across the Texas Bio Triangle. 🧬 💰 Funding: The Way I Plan to Cover Funding Announcements You may have seen reports of a local Bio & Health startup’s funding round through an SEC report filing. While some outlets have covered this, my position is not to. I prefer to support our builders directly rather than trolling the filings for scoops. There is plenty of real investigative journalism that our city would be well served by if that is where they focused. Remember I am not a journalist and I am not the media. When the company is ready to announce their round officially, I’ll gladly shout it to the rooftops. 📊 Data Peter Walker at Carta reports that in 2017, Biopharma and Medical Devices captured just under 10% of all VC dollars. By 2023, this figure rose to 17.7%, and in Q1 2024, it reached 24%. The overarching tailwinds favor our sector and region with trends towards Bio & Health and the physical & digital intersection. Energy and hardware, two other sector blossoming in Central Texas, also saw similar share gains. 🤝 M&A and Partnerships Sensi.AI, a 24/7 senior care intelligence agent, is partnering with Caring Senior Service to deploy SensiAI’s platform in Caring’s 50 locations across the US. This partnership allows seniors a better opportunity to age gracefully in their homes. 🚩 Texas Bio Triangle BioMedSA is hosting an event called Women in Bioscience, Thursday June 20th. It’s designed to connect and empower women in the bioscience industry across Central Texas, and features Randi Brosterman Hutchens discussing "Building your Personal Board." Find the link to the event in the comments. Houston-based Lokum, a staffing solution to connect clinicians and clinical staff to health care facilities, has raised a $700K pre-seed round. Congrats Ayoade (Joy) Ademuyewo on the raise. What’s Next? #AustinNext #LifeSciences #Healthcare #Biotechnology

I really enjoyed talking about digital health and partnerships on Thursday with Julia Henkels John Drakenberg Kimberley Ferguson Marissa "Missy" Pittard at the DTx Conference Series in Los Angeles, CA. Some key takeaways for the community from the great discussion are: 1. Identify partners that share the same mission and vision as your company, your team and your product/service. At OMRON Healthcare, Inc. that's going for zero, eliminating heart attacks and strokes. 2. Find champions and internal stakeholders that will advocate for a joint future vision and state. This will help build momentum and keep momentum during the long process from ideation -> development -> market launch. 3. Clearly define the joint partnership ROI and business model by understanding your partners key needs (e.g., reducing CAC) vs. just presenting YOUR solution, roadmap, needs, etc. 4. Look for partnerships where you can combine strengths to make measurable strides towards your company mission. Our partnership with AliveCor is a good example of how we applied these criteria, and its made a difference. What did we miss that's been learned in the past few years of digital health partnerships and therapeutics that can be applied moving forward?

🚀 Strategy Workshop Reflections: Navigating Challenges & Strengthening Our Team 🚀 This Thursday and Friday, my team and I came together for a highly productive strategy workshop, focusing on two key areas: 1️⃣ External and Internal Success Factors: We brainstormed on what is essential to optimize the probability of patients accessing our groundbreaking new biotech therapies. With less than 50% of new therapies available to Danish patients, this is no small task. At the same time, we’re seeing more personalized medicine and smaller, more targeted indications emerging. Thankfully, we are in a landscape where all stakeholders are solution-oriented and, most importantly, focused on improving patient outcomes. 2️⃣ Building Our Team: When I started at J&J three years ago, my ambition was to build the best patient access and policy team in Denmark—one that covers market access, regional access, health economics, pricing and tender, patient advocacy, and public policy. After 18 years in the life sciences industry, I can proudly say this is the most competent, passionate, and supportive team I’ve ever had the privilege of working with. Our "can-do" attitude, combined with positive energy, genuine empathy and willingness to support each other, makes us stronger. Grateful to work with such an exceptional group of individuals! Together, we’re ready to tackle the challenges ahead and ensure more patients can access the therapies they need. Lone J. Spiegelhauer Kasper Magaard Koldby Asbjørn Lydert Hansen Kvist Katrine Jürs Madina Saidj Lisbeth Sønderskov Anders Zeidler And a huge shout out to Kennet Hammerby for faciltating our discussions! 👏 #LifeSciences #PatientAccess #strategy #Teamwork #Innovation #HealthcareTransformation #JNJ

Research estimates that 𝟰𝟰% of Digital Health startups reach the market with low clinical robustness. [https://lnkd.in/gn4jTHPK] That’s why we've built 𝗪𝗼𝗿𝘁𝗵𝗺𝗲𝗱, a platform designed to revolutionise the landscape of digital health by connecting innovators and researchers together. Worthmed 𝘀𝘂𝗽𝗽𝗼𝗿𝘁𝘀 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗼𝗿𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝘃𝗲 𝗱𝗲𝘀𝗶𝗴𝗻, 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁, 𝗮𝗻𝗱 𝘃𝗮𝗹𝗶𝗱𝗮𝘁𝗶𝗼𝗻 of digital health solutions, using innovative participatory methods based on real-world evidence. Discover how Worthmed can empower your solution on the leaflet below. 𝗕𝗿𝗶𝗻𝗴𝗶𝗻𝗴 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗮𝗻𝗱 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝘁𝗼𝗴𝗲𝘁𝗵𝗲𝗿!

IP and Contracts- Creating value NOT Chaos- The title of my workshop at the Medilink Midlands Innovation Day on October 3rd delivered in 30 minutes...So expect some fast talking! But seriously, this will be a top tips session covering the most common issues and pitfalls we see and how to avoid/mitigate them. See you there I hope!